BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$330.01 USD
-14.59 (-4.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $329.77 -0.24 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
BIO 330.01 -14.59(-4.23%)
Will BIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIO
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
Other News for BIO
Bio-Rad Laboratories Inc (BIO) Stock Price Down 3.84% on Sep 20
Triple-Witch Says, “Remember Me?”
Labroots to Host the 12th Annual Cancer Research & Oncology Virtual Event Series on October 2nd, 2024
UBS highlights 30 stocks poised for potential moves after the Fed’s expected rate cut
Bio-Rad COO Last sells $990K in company shares